MedTrace Logo

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

NCT06490159 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-07-11

No results posted yet for this study

Summary

Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.

Conditions

Interventions

DRUG

Paclitaxel

Gastric cancer second-line chemotherapy

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Koichi Takiguchi, PhD · City of Hope Medical Center

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490159 on ClinicalTrials.gov